Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2018 | 12-2017 | 09-2017 | 06-2017 | 03-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,900 | -13,518 | -10,796 | -7,684 | -4,390 |
| Depreciation Amortization | 171 | 687 | 516 | 345 | 170 |
| Accounts payable and accrued liabilities | 411 | 1,799 | 1,799 | 1,354 | 851 |
| Other Working Capital | 988 | 2,483 | 2,398 | 1,568 | 990 |
| Other Operating Activity | -411 | -1,799 | -1,799 | -1,171 | -851 |
| Operating Cash Flow | $-1,740 | $-10,348 | $-7,882 | $-5,588 | $-3,229 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -30 | -26 | N/A | N/A |
| Investing Cash Flow | $N/A | $-30 | $-26 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 1,456 | 9,306 | 6,950 | 5,550 | 2,500 |
| Common Stock Issued | 423 | 13 | 1 | N/A | N/A |
| Financing Cash Flow | $1,879 | $9,319 | $6,951 | $5,550 | $2,500 |
| Beginning Cash Position | 106 | 1,166 | 1,166 | 1,166 | 1,166 |
| End Cash Position | 244 | 106 | 208 | 1,128 | 437 |
| Net Cash Flow | $139 | $-1,060 | $-958 | $-38 | $-729 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,740 | -10,348 | -7,882 | -5,588 | -3,229 |
| Capital Expenditure | N/A | -30 | -26 | N/A | N/A |
| Free Cash Flow | -1,740 | -10,379 | -7,908 | -5,588 | -3,229 |